

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT

DISEASE Lung cancer (NOS)

DATE OF BIRTH 24 November 1956

SEX Female

MEDICAL RECORD # Not given

PHYSICIAN

MEDICAL FACILITY Arias Stella

ADDITIONAL RECIPIENT None

MEDICAL FACILITY ID 317319

PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN ID TCC 11/24/1956

SPECIMEN TYPE Blood

DATE OF COLLECTION 18 March 2021

SPECIMEN RECEIVED 24 March 2021

Biomarker Findings

Blood Tumor Mutational Burden - 1 Muts/Mb

Microsatellite status - MSI-High Not Detected

Tumor Fraction - Cannot Be Determined

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

DNMT3A K766fs*15, R771*

JAK2 V617F

☐ Therapies with Clinical Benefit

☐ Clinical Trials

☐ Therapies with Lack of Response

BIOMARKER FINDINGS

Blood Tumor Mutational Burden - 1 Muts/Mb

Microsatellite status - MSI-High Not Detected

Tumor Fraction - Cannot Be Determined

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is an estimate of the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample based on observed aneuploid instability.

No therapies or clinical trials are associated with the Genomic Findings for this sample.

If you have questions or comments about this result, please contact your Foundation Medicine customer support representative.

Phone: 1-888-988-3639

Online: foundationmedicine.com

Email: client.services@foundationmedicine.com

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS


For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

DNMT3A - K766fs*15, R771* p. 5 **JAK2** - V617F p. 5

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *BRCA1*, *BRCA2*, *BRIP1*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF2*, *PALB2*, *PMS2*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

ORDERED TEST # ORD-1050673-01



HISTORIC PATIENT FINDINGS		ORD-1050673-01 VAF%
Blood Tumor Mutational Burden		1 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Cannot Be Determined
DNMT3A	● R771*	0.38%
	● K766fs*15	11.5%
JAK2	● V617F	0.61%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of $\geq 5\%$, and bTMB is calculated based on variants with an allele frequency of $\geq 0.5\%$.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

ORDERED TEST # ORD-1050673-01

BIOMARKER FINDINGS
BIOMARKER

Blood Tumor Mutational Burden

RESULT

1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1^{1,2} and anti-PD-1³ therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb¹. In HNSCC, a Phase 3 trial showed that bTMB ≥ 16 Muts/Mb (approximate

equivalency ≥ 8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor⁴.

FREQUENCY & PROGNOSIS

NSCLC harbors a median bTMB of 16.8 Muts/Mb (range 1.9-52.5 Muts/Mb)³. Published data investigating the prognostic implications of bTMB levels in lung cancer are limited (PubMed, Jul 2020). A large study of Chinese patients with lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)⁵. Another study of patients with NSCLC correlated elevated TMB with poorer prognosis and significantly associated lower TMB in combination with PD-L1 negative status with longer median survival in patients with lung adenocarcinoma⁶. However, no significant prognostic association of TMB and/or PD-L1 status with survival has been reported in patients with lung SCC⁶⁻⁷.

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma⁸⁻⁹ and cigarette smoke in lung cancer¹⁰⁻¹¹, treatment with temozolomide-based chemotherapy in glioma¹²⁻¹³, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes¹⁴⁻¹⁸, and microsatellite instability (MSI)^{14,17-18}. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents¹⁻³. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT

Cannot Be Determined

POTENTIAL TREATMENT STRATEGIES

Specimens with high tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw

to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management¹⁹⁻²⁴.

FREQUENCY & PROGNOSIS

Detectable ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)²⁵. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer²⁶, Ewing sarcoma and osteosarcoma²⁷, prostate cancer²², breast cancer²⁸, leiomyosarcoma²⁹, esophageal cancer³⁰, colorectal cancer³¹, and gastrointestinal cancer³².

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content³³, the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy³⁴⁻³⁵. However, the tumor fraction estimate in this sample could not be determined with confidence.

ORDERED TEST # ORD-1050673-01

GENOMIC FINDINGS

GENE

DNMT3A

ALTERATION

K766fs*15, R771*

TRANSCRIPT ID

NM_022552, NM_022552

CODING SEQUENCE EFFECT

2296_2297delAA, 2311C>T

POTENTIAL TREATMENT STRATEGIES

There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS

DNMT3A alterations have been reported at

relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2021)³⁶⁻³⁷. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2021). Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion³⁸⁻⁴³. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy³⁸⁻³⁹. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease⁴⁴. Comprehensive genomic profiling of

solid tumors detects nontumor alterations that are due to CH^{42,45-46}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

FINDING SUMMARY

The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation⁴⁷⁻⁴⁸. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor⁴⁹⁻⁵⁴. Alterations such as seen here may disrupt DNMT3A function or expression⁵⁵⁻⁵⁸.

GENE

JAK2

ALTERATION

V617F

TRANSCRIPT ID

NM_004972

CODING SEQUENCE EFFECT

1849G>T

POTENTIAL TREATMENT STRATEGIES

While JAK2 inhibitors have shown clinical benefit in hematological malignancies, clinical utility in solid tumors has not been demonstrated.

FREQUENCY & PROGNOSIS

JAK2 mutation is rare in lung tumors, reported in

3% of lung adenocarcinomas and squamous cell carcinomas⁵⁹. Increased expression and activity of JAK2 has been reported in non-small cell lung cancer (NSCLC), cited in 57-79% of cases, and has been correlated with activation of the STAT3 pathway⁶⁰⁻⁶¹. High expression of the JAK2-STAT3 pathway has been associated with decreased survival in patients with NSCLC⁶¹. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion³⁸⁻⁴³. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy³⁸⁻³⁹. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular

disease⁴⁴. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{42,45-46}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

FINDING SUMMARY

JAK2 encodes Janus kinase 2, a tyrosine kinase that regulates signals triggered by cytokines and growth factors⁶². JAK2 is often mutated in hematopoietic and lymphoid cancers. The JAK2 alteration observed here has been characterized as activating and is predicted to be oncogenic⁶²⁻⁷⁷. Limited clinical data suggest that JAK2 V617F mutations detected in solid tumors may originate from infiltrating hematopoietic cells and not the tumor itself⁷⁸.

ORDERED TEST # ORD-1050673-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

BRD4
E1326D

EGFR
E319D

FAM46C
V373I

FUBP1
P551L

ID3
T105A

IRS2
A701_V702insA

MLL2
R5266H

MTOR
E2456K

PALB2
L939W

TSC1
K587R

TYRO3
G68R

APPENDIX

Genes assayed in FoundationOne®Liquid CDx

ORDERED TEST # ORD-1050673-01

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 Exons 4-9	ACVR1B	AKT1 Exon 3	AKT2	AKT3	ALK Exons 20-29, Introns 18, 19	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF Exons 4, 5, 7, 11, 13, 15, 16	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BCR* Introns 8, 13, 14	BRAF Exons 11-18, Introns 7-10	BRCA1 Introns 2, 7, 8, 12, 16, 19, 20	BRCA2 Intron 2	BRD4	BRIP1	BTG1
BTG2	BTK Exons 2, 15	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL
CCND1	CCND2	CCND3	CCNE1	CD22	CD70	CD74* Introns 6-8	CD79A	CD79B
CD274 (PD-L1)	CDC73	CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B
CDKN2A	CDKN2B	CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL
CSF1R	CSF3R	CTCF	CTNNA1	CTNNB1 Exon 3	CUL3	CUL4A	CXCR4	CYP17A1
DAXX	DDR1	DDR2 Exons 5, 17, 18	DIS3	DNMT3A	DOT1L	EED	EGFR Introns 7, 15, 24-27	EP300
EPHA3	EPHB1	EPHB4	ERBB2	ERBB3 Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25	ERBB4	ERCC4	ERG	ERRF1
ESR1 Exons 4-8	ETV4* Intron 8	ETV5* Introns 6, 7	ETV6* Introns 5, 6	EWSR1* Introns 7-13	EZH2 Exons 4, 16, 17, 18	EZR* Introns 9-11	FAM46C	FANCA
FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14	FGF19
FGF23	FGF3	FGF4	FGF6	FGFR1 Introns 1, 5, Intron 17	FGFR2 Intron 1, Intron 17	FGFR3 Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17	FGFR4	FH
FLCN	FLT1	FLT3 Exons 14, 15, 20	FOXL2	FUBP1	GABRA6	GATA3	GATA4	GATA6
GNA11 Exons 4, 5	GNA13	GNAQ Exons 4, 5	GNAS Exons 1, 8	GRM3	GSK3B	H3F3A	HDAC1	HGF
HNFI1A	HRAS Exons 2, 3	HSD3B1	ID3	IDH1 Exon 4	IDH2 Exon 4	IGF1R	IKBKE	IKZF1
INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2 Exon 14	JAK3 Exons 5, 11, 12, 13, 15, 16	JUN	KDMSA
KDMSA	KDM6A	KDR	KEAP1	KEL	KIT Exons 8, 9, 11, 12, 13, 17, Intron 16	KLHL6	KMT2A (MLL) Introns 6, 8-11, Intron 7	KMT2D (MLL2)

© 2021 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Lani Clinton, M.D., Ph.D. | 31 March 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1050673-01

APPENDIX

Genes assayed in FoundationOne®Liquid CDx

KRAS	LTK	LYN	MAF	MAP2K1 (MEK1) Exons 2, 3	MAP2K2 (MEK2) Exons 2-4, 6, 7	MAP2K4	MAP3K1	MAP3K13
-------------	------------	------------	------------	------------------------------------	---	---------------	---------------	----------------

APPENDIX

Genes assayed in FoundationOne®Liquid CDx

ORDERED TEST # ORD-1050673-01

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MERTK	MET
MITF	MKNK1	MLH1	MPL Exon 10	MRE11A	MSH2 Intron 5	MSH3	MSH6	MST1R
MTAP	MTOR Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56	MUTYH	MYB* Intron 14	MYC Intron 1	MYCL (MYCL1)	MYCN	MYD88 Exon 4	NBN
NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2 Intron 26	NOTCH3	NPM1 Exons 4-6, 8, 10
NRAS Exons 2, 3	NSD3 (WHSC1L1)	NTSC2	NTRK1 Exons 14, 15, Introns 8-11	NTRK2 Intron 12	NTRK3 Exons 16, 17	NUTM1* Intron 1	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA Exons 12, 18, Introns 7, 9, 11
PDGFRB Exons 12-21, 23	PDK1	PIK3C2B	PIK3C2G	PIK3CA Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1 Exons 3, 4, 6, 7, 10, 14, 15, 17, Introns 4-8	RARA Intron 2	RB1	RBM10	REL	RET Introns 7, 8, Exons 11, 13-16, Introns 9-11
RICTOR	RNF43	ROS1 Exons 31, 36-38, 40, Introns 31-35	RPTOR	RSPO2* Intron 1	SDC4* Intron 2	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SLC34A2* Intron 4	SMAD2	SMAD4	SMARCA4	SMARCB1
SMO	SNCAIP	SOC31	SOX2	SOX9	SPEN	SPOP	SRC	STAG2
STAT3	STK11	SUFU	SYK	TBX3	TEK	TERC* ncRNA	TERT* Promoter	TET2
TGFBR2	TIPARP	TMPPRSS2* Introns 1-3	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3
U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1	XRCC2	ZNF217	ZNF703

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

ORDERED TEST # ORD-1050673-01

APPENDIX

About FoundationOne®Liquid CDx

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.



ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted

cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also detects select genomic rearrangements, select copy number alterations, tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF ALTERATIONS AND THERAPIES

Biomarker and Genomic Findings

Therapies are ranked based on the following criteria: Therapies with clinical benefit in patient's tumor type (ranked alphabetically within each NCCN category) followed by therapies with clinical benefit in other tumor type (ranked alphabetically within each NCCN category).

Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of $\geq 5\%$, and bTMB is calculated based on variants with an allele frequency of $\geq 0.5\%$.
8. Tumor fraction is the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from observed aneuploid instability in the sample.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

ORDERED TEST # ORD-1050673-01

APPENDIX

About FoundationOne®Liquid CDx

to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters with no conflicts), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories please refer to the NCCN Compendium®.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or

repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 3.0.0

ORDERED TEST # ORD-1050673-01

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Xiao D, et al. Oncotarget (2016) pmid: 27009843
6. Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500
7. Yu H, et al. J Thorac Oncol (2019) pmid: 30253973
8. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
9. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
10. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
11. Rizvi NA, et al. Science (2015) pmid: 25765070
12. Johnson BE, et al. Science (2014) pmid: 24336570
13. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
14. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
15. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
16. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
17. Nature (2012) pmid: 22810696
18. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
19. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
20. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
21. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
22. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
23. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
24. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
25. Bettgowda C, et al. Sci Transl Med (2014) pmid: 24553385
26. Lapin M, et al. J Transl Med (2018) pmid: 30400802
27. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
28. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
29. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
30. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
31. Fan G, et al. PLoS ONE (2017) pmid: 28187169
32. Vu et al., 2020; DOI: 10.1200/PO.19.00204
33. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
34. Zhang EW, et al. Cancer (2020) pmid: 32757294
35. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
36. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
37. Gao J, et al. Sci Signal (2013) pmid: 23550210
38. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
39. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
40. Xie M, et al. Nat. Med. (2014) pmid: 25326804
41. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
42. Severson EA, et al. Blood (2018) pmid: 29678827
43. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
44. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
45. Chabon JJ, et al. Nature (2020) pmid: 32269342
46. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
47. Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773
48. Prog Mol Biol Transl Sci (2011) pmid: 21507354
49. Yang J, et al. Mol Med Rep (2011) pmid: 21887466
50. Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044
51. Daskalos A, et al. Cancer (2011) pmid: 21351083
52. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317
53. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581
54. Kim MS, et al. APMIS (2013) pmid: 23031157
55. Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382
56. Guo X, et al. Nature (2015) pmid: 25383530
57. Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090
58. Zhang ZM, et al. Nature (2018) pmid: 29414941
59. Campbell JD, et al. Nat. Genet. (2016) pmid: 27158780
60. Looyenga BD, et al. PLoS ONE (2012) pmid: 22319590
61. Zhao M, et al. Lung Cancer (2011) pmid: 21333372
62. Jatiani SS, et al. Genes Cancer (2010) pmid: 21442038
63. Bicsak TA, et al. J. Biol. Chem. (1989) pmid: 2491854
64. Zhao L, et al. J. Biol. Chem. (2009) pmid: 19638629
65. Walz C, et al. J. Biol. Chem. (2006) pmid: 16632470
66. Kralovics R, et al. N. Engl. J. Med. (2005) pmid: 15858187
67. Etheridge SL, et al. Blood (2014) pmid: 24381227
68. Marty C, et al. Blood (2014) pmid: 24398328
69. Ma W, et al. J Mol Diagn (2009) pmid: 19074595
70. Wu QY, et al. Leuk. Lymphoma (2013) pmid: 23452118
71. Mullighan CG, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19470474
72. Yoda A, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018760
73. Mercher T, et al. Blood (2006) pmid: 16804112
74. Zou H, et al. FEBS Lett. (2011) pmid: 21362419
75. Funakoshi-Tago M, et al. J. Biol. Chem. (2009) pmid: 19289461
76. Grisouard J, et al. Blood (2016) pmid: 27288519
77. Scott LM, et al. N. Engl. J. Med. (2007) pmid: 17267906
78. Riedlinger G, et al. JAMA Oncol (2019) pmid: 30605212